Viatris (VTRS) Operating Income Growth (3y) (2023 - 2026)
Viatris (VTRS) Operating Income Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.74 Bn | 86.88 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.87 Bn | 32.13 Bn | 1.97 Bn | 273.62% |
| 3 | Zoetis | 32.28 Bn | 30.34 Bn | 1.62 Bn | 3.84% |
| 4 | Takeda Pharmaceutical | 27.51 Bn | 23.45 Bn | 4.39 Bn | -59.82% |
| 5 | United Therapeutics | 23.14 Bn | 20.98 Bn | 648.10 Mn | 4.63% |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.25 Bn | 18.44 Bn | 1.16 Bn | -30.05% |
| 8 | Neurocrine Biosciences | 17.89 Bn | 16.57 Bn | 800.70 Mn | 54.58% |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | 40.17% |
| 10 | Vireo Growth | 10.52 Bn | 10.37 Bn | 59.30 Mn | 190.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.05% |
| Dec 31, 2025 | 1.44% |
| Sep 30, 2025 | -31.66% |
| Jun 30, 2025 | -24.84% |
| Mar 31, 2025 | -82.46% |
| Dec 31, 2024 | -32.33% |
| Sep 30, 2024 | -14.20% |
| Jun 30, 2024 | -71.21% |
| Mar 31, 2024 | 40.37% |
| Dec 31, 2023 | 19.80% |
| Mar 31, 2023 | 29.36% |